Orchid Pharma Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
Orchid Pharma reported Q4 FY26 standalone revenue of approximately Rs 238 crore, broadly stable versus Rs 237 crore in Q4 FY25, while full-year FY26 revenue fell to Rs 811 crore from Rs 922 crore in FY25 amid industry-wide pricing pressure in Cephalosporins. Management said gross margins recovered in Q4 after inventory revaluation losses hurt earlier quarters, and discussed progress on the 7ACA project, Exblifep commercialization, Cefiderocol facility, and the pending merger with Dhanuka Laboratories. Management also outlined plans to build fill-finish and formulation capabilities to target the U.S. sterile Cephalosporin market.